Mechanistic Roles of Long mcRNA-regulated Gene Transcription in Prostate Cancer

长 mRNA 调控的基因转录在前列腺癌中的机制作用

基本信息

  • 批准号:
    8653043
  • 负责人:
  • 金额:
    $ 23.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-06-15 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary Prostate cancer is the most common non-skin malignancy in men and is responsible for more deaths than any other cancer, except for lung cancer. According to the American Cancer Society (ACS), about 218,890 new cases of prostate cancer were diagnosed in the United States during 2007 and about 1 man in 6 will be diagnosed with prostate cancer during his lifetime. It is well established that androgen plays an important role in promoting prostate cancer initiation/development. Therefore, it is essential to understand the mechanism of androgen receptor (AR) target gene expression, which is at the center stage of prostate cancer research. Although our knowledge of the molecular mechanisms by which the AR regulates gene transcription and its possible link to prostate cancer is increasing, several interesting questions remain to be answered. Thus, the major hypothesis in this proposal is that ncRNA-dependent relocation of gene regulatory regions based on covalent modifications of specific histone mark "readers," such as Pc2, are critical components of the regulatory machinery underlying the transcriptional actions of nuclear receptors, including AR. Specifically, the proposed study aims to: 1) define non-histone methylation/demethylation of Pc2 as a novel molecular strategy responsible for genome-wide AR transcriptional programs; 2) determine the androgen-induced relocation of AR target genes between PcG bodies and interchromatin granules and the potential involvement of ncRNAs; 3) investigate the role of ncRNAs in modulating androgen-dependent gene regulatory programs and their potential relevance for the prostate cancer development. The major novel aspect of this study is that it uncovers a new component of the regulatory machinery required for androgen-dependent gene regulatory programs by providing a biologically and clinically innovative mechanism by which AR-targeted genes are regulated, in part, by the dynamic ligand-dependent relocation from transcriptional repressive to permissive nuclear bodies involving the functional interplay between the non-histone Pc2 methylation events and the resultant specific ncRNA associations. Generally, this mechanism may serve to integrate actions of transcription factor/co-regulators, non-histone protein methylation, and ncRNAs resident in distinct subnuclear architectural structures to achieve coordinated activation for nuclear receptor target genes. The results from the proposed study may facilitate the development of novel prostate diagnosis and therapeutic strategies.
项目摘要 前列腺癌是男性最常见的非皮肤性恶性肿瘤,导致的死亡人数更多。 比任何其他癌症都要多,除了肺癌。根据美国癌症协会(ACS)的数据,大约 2007年,美国新诊断出218,890例前列腺癌病例,约每6人中就有1人被诊断出患有前列腺癌 将在他的有生之年被诊断出患有前列腺癌。众所周知,雄激素对人体健康的影响 在促进前列腺癌发生/发展中的重要作用。因此,有必要了解 前列腺癌中心期雄激素受体(AR)靶基因表达的机制 研究。尽管我们对AR调节基因转录的分子机制的了解 而且它与前列腺癌的可能联系正在增加,几个有趣的问题仍然有待回答。 因此,这个建议的主要假设是依赖于ncRNA的基因调节区的重新定位。 基于特定组蛋白标记的共价修饰,读取器,如PC2,是 核受体转录活动的调控机制,包括AR。具体地说, 拟议的研究旨在:1)将PC2的非组蛋白甲基化/去甲基化定义为一种新的分子策略 负责全基因组AR转录程序;2)确定雄激素诱导的AR重新定位 PcG小体和间染色质颗粒之间的靶基因及ncRNAs的潜在参与;3) 研究ncRNAs在调节雄激素依赖性基因调控程序中的作用及其机制 与前列腺癌发展的潜在相关性。这项研究的主要新奇之处在于它 发现雄激素依赖基因调控所需的调控机制的一个新组成部分 通过提供一种生物和临床创新机制,使AR靶向基因 部分受配体依赖的动态重新定位从转录抑制到允许的调节 核小体涉及非组蛋白PC2甲基化事件和 由此产生的特定的ncRNA关联。一般而言,该机制可用于整合 转录因子/共调节因子、非组蛋白甲基化和位于不同亚核的ncRNAs 构建结构,以实现核受体靶基因的协调激活。结果来自于 这项拟议的研究可能有助于开发新的前列腺癌诊断和治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Liuqing Yang其他文献

Liuqing Yang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Liuqing Yang', 18)}}的其他基金

Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast Cancer
三阴性乳腺癌中 PARP 抑制剂的合理联合治疗
  • 批准号:
    10015209
  • 财政年份:
    2017
  • 资助金额:
    $ 23.41万
  • 项目类别:
Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast Cancer
三阴性乳腺癌中 PARP 抑制剂的合理联合治疗
  • 批准号:
    10229578
  • 财政年份:
    2017
  • 资助金额:
    $ 23.41万
  • 项目类别:
Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast Cancer
三阴性乳腺癌中 PARP 抑制剂的合理联合治疗
  • 批准号:
    9764288
  • 财政年份:
    2017
  • 资助金额:
    $ 23.41万
  • 项目类别:
Combinatorial Treatment Strategies to Counteract EGFR Resistance
对抗 EGFR 耐药性的组合治疗策略
  • 批准号:
    10247729
  • 财政年份:
    2017
  • 资助金额:
    $ 23.41万
  • 项目类别:
Combinatorial Treatment Strategies to Counteract EGFR Resistance
对抗 EGFR 耐药性的组合治疗策略
  • 批准号:
    9362260
  • 财政年份:
    2017
  • 资助金额:
    $ 23.41万
  • 项目类别:
Combinatorial Treatment Strategies to Counteract EGFR Resistance
对抗 EGFR 耐药性的组合治疗策略
  • 批准号:
    9751236
  • 财政年份:
    2017
  • 资助金额:
    $ 23.41万
  • 项目类别:
Mechanistic Roles of Long mcRNA-regulated Gene Transcription in Prostate Cancer
长 mRNA 调控的基因转录在前列腺癌中的机制作用
  • 批准号:
    8682888
  • 财政年份:
    2013
  • 资助金额:
    $ 23.41万
  • 项目类别:
Mechanistic Roles of Long mcRNA-regulated Gene Transcription in Prostate Cancer
长 mRNA 调控的基因转录在前列腺癌中的机制作用
  • 批准号:
    8862424
  • 财政年份:
    2013
  • 资助金额:
    $ 23.41万
  • 项目类别:
Role of ncRNA-mediated Relocation of AR Transcription Units in Prostate Cancer
ncRNA 介导的 AR 转录单位重定位在前列腺癌中的作用
  • 批准号:
    8281227
  • 财政年份:
    2012
  • 资助金额:
    $ 23.41万
  • 项目类别:

相似海外基金

Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
  • 批准号:
    DP230103210
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
    Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
  • 批准号:
    10584689
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
  • 批准号:
    10650956
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
  • 批准号:
    10488954
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
  • 批准号:
    10651105
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
  • 批准号:
    10603636
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
Androgen receptor function in melanoma
雄激素受体在黑色素瘤中的功能
  • 批准号:
    10416658
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
  • 批准号:
    10544062
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
  • 批准号:
    10534943
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
  • 批准号:
    10677989
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了